It's a good idea to teach children to save from a young age, so they'll be more likely to handle money wisely when they're older. Opening a savings account in your child's name is also a good idea, as this will help hugely towards the costs of university education, a first car, starting a business or a deposit on a house. The importance of this in the current economic climate cannot be overlooked.
There are a variety of options when it comes to children's savings, with some more popular than others, and below we have a list of the most common options you may come across.
Just £1 usually gets your child started with one of these bank accounts, and they'll usually be able to withdraw money when they want with their own bank card. The interest rates will vary between accounts, so it is necessary to shop around. Ask you bank for more information.
These accounts ensure your child's money grows at the same rate of interest throughout the length of the plan, and are designed for long-term savings. However, if interest rates rise during the fixed term you'll obviously get less return. But, fixed rate interest accounts do offer reassurance for times when the interest rate dips too.
Trusts are managed by somebody who invests the money on your child's behalf. You can build it up until your child reaches a certain age or sell your investments at any time. Be sure to check if charges and annual running costs apply.
National Savings & Investments are run by the government, and offer a tax-free way to save for your child through a mix of savings certificates, premium bonds and ISAs.
The odds are currently 24,000 to 1 to win anything with premium bonds. But somebody's got to win! You don't get any interest, but these are a safe way to build a fund for your child - tax free. Parents must buy the bonds for kids under 16.
Any interest earned on children's bonds is completely tax free. They must be purchased by an adult and can be cashed in when the child reaches 21. Although the rates of interest are often slightly lower than general, children's savings accounts usually have fixed rates of interest which offers peace of mind.
ISA's are the most popular savings schemes on the market, and with the launch of the JISA in November 2011, a new method of saving was born. JISA's allow you to spread your child's money over a range of different investments including shares and stocks in businesses. They are also tax-exempt on growth of the fund as well as any money received on maturity, making them a fantastic way to save. But shop around; there are many choices with different advantages.
Pensions for children? Well not quite but you can start one off for them when they are young. You can save a maximum £2,808 each year and, in addition, the Inland Revenue adds a welcome 22% tax relief. This would bring your child's annual savings to around £3,600. Its flexibility allows you to pay in money when you want - your child won't be getting thier hands on it until they're 55 though!


text:
Home > NOVELLAS
Rime [hardcover] by Tim Lebbon
SCIENCE FICTION Novella - Unsigned Jacketed Hardcover. A signed and numbered edition limited to 100 copies is also available.
Unsigned Jacketed Hardcover Signed JHC Limited to 100 copies
A NOVELLA by Tim Lebbon
CATEGORY Science Fiction
PUBLICATION DATE October 2018
COVER ART Ronnie Jensen
Unsigned Jacketed Hardcover — ISBN 978-1-786363-86-2
100 Jacketed Hardcovers signed by Tim Lebbon — ISBN 978-1-786363-87-9
In search of a new home after the downfall of planet Earth, the massive generation ship Cradle carries seventeen million souls in cryosleep.
One man, a control room technician, is part of a generation destined to live and die protecting these sleeping millions.
When Cradle encounters five unknown entities in the deepest reaches of interstellar space, he makes a fateful decision that will affect the future of the entire human race.
'Rime' is a powerful retelling of The Rime of the Ancient Mariner set against the cold, inhospitable backdrop of deep space.
Tim Lebbon's is a New York Times-bestselling author of over forty novels. Recent books include The Folded Land, Relics, The Family Man, The Silence and the Rage War trilogy of Alien/ Predator novels. He has won four British Fantasy Awards, a Bram Stoker Award, and a Scribe Award, and has been a finalist for the Shirley Jackson and World Fantasy Awards. The movie of his story Pay the Ghost, starring Nicolas Cage, was released Hallowe'en 2015. The Silence, starring Stanley Tucci and Kiernan Shipka, is due for release in 2018. Several other movie projects are in development in the US and UK.
Find out more about Tim at his website www.timlebbon.net

redpajama_set_name: RedPajamaCommonCrawl


8mm Red Abacus Glass Beads, ~44 pcs per 14" strand; hole 1mm. Austrian Crystal style.
These glass beads are great on jewelry accessories such as necklaces, earrings, and bracelets. Beautiful beads for your creative jewelry making project or craft supplies. Create necklaces, bracelets, anklets, beaded jewelry, custom jewelry and handmade jewelry.


There was some fighting talk from Sebastian Vettel as Ferrari topped their first Friday practice session of the season at Silverstone.
Vettel, who comes into the British Grand Prix weekend as World Championship leader again, was quickest in FP2 with a 1:27.552 set on soft tyres.
Mercedes' Lewis Hamilton, initially quickest in FP1, narrowed the gap to Vettel to 0.187 seconds in the afternoon session, while Valtteri Bottas was three tenths down in P3.
Ferrari are usually slow starters on Friday with their engine turned all the way down, but Vettel is hoping that he has now set the foundation for the Scuderia to end Mercedes' dominance at Silverstone.
"It's been a good Friday. We've had rough Fridays, but for a change, it seems like a good Friday," Vettel said.
"We try to kill their [Mercedes'] magic, obviously that's what we have tried over the last years and I think here and there we have succeeded quite well.
"It's true that they are very strong around here and we expect them to be very strong tomorrow, but I hope we can be there and I hope we can be close. That would be very good news.
Kimi Raikkonen was four tenths off the pace in P4.


Anyone who is interested in financial markets and is willing to share their market opinions is welcome to vote on our platform.
Users can vote on their prediction of the direction of a choice of indices and currencies by submitting their views on markets being (very) bearish, (very) bullish or neutral. The votes form the basis for the Swarmsurge investment strategy.
On our platform the users can track their own performance and also see how well they are doing in relation to the other users. We group the users into deciles, which are displayed on the user's performance page.
The votes are counted once per day at 08:00 GMT+1. However, there is no need to vote every day since a cast vote will remain in its position until changed. This allows the user to follow his desired investment time horizon.
Swarmsurge regularly runs investment competitions with cash prizes for the best performers. For more information click here. If you are interested to try it out, just register here. Participation is free and without any catches as we are always in need of new voters.


text:
About Hemophilia
Hemophilia Types
Hemophilia Type A
Hemophilia Type B
Hemophilia B Leyden
Hemophilia Type C
Acquired Hemophilia
Causes of Hemophilia
Symptoms of Hemophilia
Diagnosis of Hemophilia
Hemophilia Prognosis
Living with Hemophilia
Hemophilia and Pregnancy
Post-Natal Period
Facts about Hemophilia
Antifibrinolytics
Cyklokapron (Tranexamic Acid)
Bypassing Agents
FEIBA
NovoSeven
Obizur
Sevenfact
Replacement Therapy
Jivi (Previously BAY 94-9027)
Nuwiq
Extended Half-Life (EHL) Products
Albumin Fusion
CSL654 (Idelvion)
Fc Fusion
Alprolix for Hemophilia B
Esperoct
Ixinity
Advate
Adynovate
Afstyla for Hemophilia A
Hemlibra (Emicizumab-KXWH)
Kovaltry for Hemophilia A
Kogenate for Hemophilia A
Recombinate
Refixia (N9-GP) for Hemophilia B
BAY 94-9027 for Hemophilia A
BAX 855 for Hemophilia A
BIVV001
N8-GP for Hemophilia A
TRM-201 (Rofecoxib)
AMT-060 for Hemophilia B
AMT-061 (etranacogene dezaparvovec)
FLT180a
SB-525 for Hemophilia A
SB-FIX
SPK-8011
Roctavian (formerly Valrox/BMN 270)
The Forgotten Factor
Hemophilia 24/7
In the Twinkling of an Eye
The 'I' in Hemophilia
HemoWife
Rare Disease Patient Groups Unite to Preserve Orphan Drug Tax Credit in US
by Larry Luxner
Click here to subscribe to the Hemophilia News Today Newsletter!
The National Organization for Rare Disorders (NORD) says it's "disappointed and dismayed" after the House of Representatives voted 227-205 last week to repeal the Orphan Drug Tax Credit as part of a U.S. tax reform package.
A similar package before the Senate Finance Committee does not repeal the credit entirely, but cuts incentives nearly in half by lowering its value from 50 percent of qualified clinical testing expenses to 27.5 percent.
A statement signed by 91 patient organizations under the NORD umbrella noted that without the Orphan Drug Tax Credit, new therapies for rare disease patients could tumble by more than a third.
"We will not stand idly by as Congress deliberates on diminishing the hope of the 95 percent of individuals with a rare disease still waiting for their very first treatment," the petition, released Nov. 20, reads. "Any proposal that stands in their way to finally obtaining a safe and effective therapy is unacceptable."
Dozens of groups ranging from the Alport Syndrome Foundation and the ALS Association to the Consortium of Multiple Sclerosis Centers, Parent Project Muscular Dystrophy and the Friedreich's Ataxia Research Alliance endorsed the statement.
NORD, a nonprofit organization formed in 1983 — the same year President Reagan signed the Orphan Drug Act into law — says the tax incentives this law offers to U.S. pharmaceutical companies are crucial in spurring the development of new therapies.
The New York Times reported Nov. 8 that the tax credit — whose elimination could save the government an estimated $54 billion over the next decade — "has come under scrutiny because critics say that some major drugmakers have exploited it by obtaining the orphan designation for billion-dollar blockbuster drugs like Humira for treating rheumatoid arthritis and Crestor, the cholesterol drug, that were already on the market."
Paul Melmeyer, director of federal policy at NORD, discusses 2018 legislative priorities at the recent summit. (Photos by Larry Luxner)
But a study commissioned by NORD and released Oct. 17 during the organization's Rare Diseases & Orphan Products Breakthrough Summit in Washington, D.C., found that approved drugs for orphan indications accounted for only $36 billion, or 7.9 percent, of the $460 billion Americans spent on pharmaceuticals in 2016.
According to the 32-page report, "Orphan Drugs in the United States: Providing Context for Use and Cost," the median annual cost for an orphan drug in 2016 came to $32,880, but the 10 therapies used most by patients averaged $14,909.
Speaking at the summit, Paul Melmeyer, NORD's director of federal policy, said the tax credits enshrined in the 1983 act have led to the approval of 451 orphan drugs for 590 rare disease indications since its passage.
"There is still a ton of misinformation out there on what the Orphan Drug Act does and does not do. If the orphan drug tax credit were repealed, we'd see one-third fewer drugs going forward, so we're trying to do our best to emphasize to Congress how important this tax credit is to our rare disease community," he said. "We believe that'll be one of the most important roles we'll be playing over the course of the next 12 months."
State legislation also of concern
While the Orphan Drug Act has certainly grabbed headlines, it's not the only legislative issue on NORD's radar screen.
"NORD was incredibly active this summer fighting harmful changes to the Affordable Care Act," said Tim Boyd, the organization's director of state policy. "The changes that were being proposed were very harmful. This will continue to be a priority for us."
In fact, various proposals at the state level concern the rare disease community as well, especially when they reportedly conflict with guidelines set by the U.S. Food and Drug Administration (FDA).
One example, say NORD officials, is the Massachusetts 1115 Waiver program. This program expands MassHealth — the state Medicaid program — to low-income families, but rations medicines to children and the elderly.
"We have recently seen a disturbing trend where states are ignoring what the FDA says about drug safety and effectiveness," Boyd said. "This has resulted in rising out-of-pocket costs for drugs, patients getting substandard treatment, or no treatment at all."
The 1115 Waiver could "potentially limit access to new and innovative" FDA-approved therapies made possible through the 21st Century Cures Act, which Congress approved in December 2016 with widespread bipartisan support.
"Restricting MassHealth's drug benefits to a closed formulary would limit the ability of providers to make the best medical decisions for the care of their patients, effectively taking the clinical care decisions away from the doctor and patient, and giving it to the state," stated an Oct. 18 letter to Eric Hargan, acting secretary of the U.S. Department of Health and Human Services. The letter was signed by NORD and more than 100 other advocacy groups.
Other "states to watch" when it comes to the 21st Century Cures Act, said Boyd, include Minnesota, New Jersey and Oregon.
"We find that many decisions about utilization are made without allowing patients to weigh in," he said. "We believe states are making decisions about who gets a drug and who doesn't, without consulting experts in the field about these diseases. This is really disturbing to us."
Other priorities
Other priorities include increased federal funding for newborn rare disease screening programs, and expanding insurance coverage for medical foods.
To that end, Melmeyer said NORD supports the creation of an Office of Patient Affairs, as well as passage of a Medical Nutrition Equity Act.
"Currently, insurance coverage for medical nutrition is awful. We need to cover it. It's medically necessary," he said. "We must also improve access to pre-approval therapies. Right now, we have an expanded access program which is working for a lot of people, but we think it could work for even more people."
Another hot-button issue is so-called "Right To Try" legislation, which allows terminally ill patients to try therapies that have passed the FDA's Phase 1 clinical trial process but are not yet commercially available. So far, 37 states have passed Right To Try laws; several others are considering similar legislation.
Copies of Victoria Jackson's book, "The Power of Rare," were displayed at the NORD summit.
According to the Phoenix-based Goldwater Institute, more than one million Americans die from terminal illnesses every year, yet fewer than 3 percent gain access to investigational treatments through clinical trials.
"Compassionate use exceptions are only granted to about 1,000 patients a year," says a fact sheet on the institute's website. "Many patients run out of time before they can qualify for the exemption … Right To Try laws help patients gain immediate access to the medical treatments they need before it's too late."
Said Melmeyer: "Our goal is to expand access to investigational therapies for those who do not qualify. But it's not the FDA withholding access, it's the companies."
FDA Commissioner Scott Gottlieb weighed in on the issue at the NORD summit.
"We are fully committed to the goals of getting patients earlier access when they've exhausted other options," said Gottlieb, a keynote speaker at the summit. "But there are various obstacles. There just isn't product available in many cases because of manufacturing issues. Companies are using batches developed just for the purpose of clinical trials that have to be rationed, even in a pre-approval setting."
Martha Rinker, NORD's vice president of policy, said she expects two or three hearings on this topic, but Right to Try "is probably not going to see legislation on the federal level."
Melmeyer advised the many patient advocates attending NORD's event to "get to know the individuals at the FDA" who can help organizations navigate federal bureaucracy — and to keep pressure on Congress to do what's right for the estimated 30 million Americans with rare diseases.
"All the folks who called their congressmen, tweeted or sent that email, made that video or Facebook post, they were so effective," he said of past efforts. "It was the perfect testament to the power of advocacy — and why we need to be involved."
Larry Luxner
Florida native Larry Luxner, a veteran journalist and photographer, has reported from more than 100 countries in Latin America, Africa, Eastern Europe, the Middle East and Asia for the Miami Herald, the Washington Diplomat, the Journal of Commerce and other news outlets. He lived for many years in San Juan, Puerto Rico, and the Washington, D.C., area. Among other ventures, he launched a monthly newsletter, South America Report, and later published CubaNews for 12 years before relocating to Israel in January 2017 and joining BioNews — first as a copy editor and now as a staff writer. Larry is fluent in Spanish, Portuguese and Hebrew, and enjoys taking long walks around Tel Aviv in his spare time.
Tagged #NORDsummit, 21st Century Cures Act, FDA, NORD, orphan drug act, rare diseases, Right to Try.
Previous: The Challenges of Caring for Older Hemophilia Patients
Next:33 Iron-Rich Foods to Add to Your Diet
Recent Hemophilia Articles
Fresh Look at Mechanism Finds 'Important Role' in Factor VIII Regulation
'In the Twinkling of an Eye': The Moments That Change Our Lives
Roctavian, Hem A Gene Therapy, Sustains Drop in Bleeding Rates, Phase 3 Data Show
Create your own user feedback survey
The Roles We Play as Caregivers
How to Help Your Doctor Take Hemophilia Seriously
Hemophilia News Today
Hemophilia News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.


NZH An outstanding companion for all vegetables especially tomatoes, peppers, eggplants and potatoes. A bush type marigold also known as French marigold with gorgeous orange and deep red single flowers. The scent from plant and root matter is said to deter several insect pests including whitefly and nematodes simultaneously accumulating phosphorus in the soil. Interplant in the vegetable garden to attract pollinators. Annual, height to 40cm, frost tender.
Sow in Spring or Late Summer for continuous colour in the garden. Direct scatter sow in borders and rows, or sow into trays and prick out to 4cm diagonal spacing when true leaves appear. Transplant out to 30cm diagonal spacing in fertile soil. This seed is hard to process and we include lots because some of the seeds will be immature. Sow thickly for best results.


text:
Research aims to reduce barriers for women fleeing violence
Monday, Nov. 25, marks the International Day for the Elimination of Violence Against Women. According to the United Nations, violence is as serious a cause of death among young women as cancer, and a greater cause of injury than traffic accidents.
For women looking to flee domestic violence, there are supports within the community, but those supports don't always take into account the needs of women with companion animals. As a result, some women delay exiting violent relationships, or return to those relationships out of concern for their animals, putting themselves at great risk of harm.
Dr. Rochelle Stevenson, assistant professor of sociology, is working alongside the University of Windsor's Dr. Amy Fitzgerald, Dr. Betty Barrett, and Dr. Patti Timmons-Fritz on research that explores the intersection of violence against women and violence against animals, and their research has illuminated a gap in services for women wishing to leave abusive relationships.
The goal of their research is not only to create a better understanding of the barriers that exist that prevent women from leaving violent homes, but also to work directly with service providers to address some of these complexities. The research not only assesses the scope of animal abuse as it intersects with intimate partner violence, but will determine the best strategies for addressing the needs of abused women, and the researchers will share that information with practitioners and policymakers in order to develop programs that reduce barriers to access.
The researchers have data from nearly 1,000 shelters and transition houses in Canada and the United States, which shows that when a woman first reaches out for help, very few support workers ask about pets in the home, assuming that if there is a pet present, and if it is important, the woman will bring it up.
But Stevenson says that's rarely the case, even though more transition homes are beginning to offer on-site pet services, or are partnering with local animal rescues to offer emergency shelter pet programs.
Fitzgerald, A. J., Barrett, B. J., Stevenson, R., & Cheung, C. H. (2019). Animal Maltreatment in the Context of Intimate Partner Violence: A Manifestation of Power and Control? Violence Against Women, 25(15), 1806–1828. https://doi.org/10.1177/1077801218824993
"There's a notion that shelters are for women and children only, and there is already so much shame and guilt about asking for help in the first place that women may be hesitant to ask for a safe space for their companion animals as well. "The support worker is the best person to open that conversation," said Stevenson.
She knows that a woman might delay leaving a violent home for months, or even years, because she doesn't want to leave her animals behind, which leaves her in a very dangerous situation. "Right before she leaves, and right after she returns, she is at the highest risk for intimate partner homicide," Stevenson said. "In our study, one-third of women report considering returning to their partner because they still had pets in the home. It is such a huge risk, but it also shows the strength of that human-pet relationship."
Stevenson has been researching the intersection of intimate partner violence and animal abuse for more than a decade.
"My own animals are so important to me, so the idea of having to leave one behind is heartbreaking," she said.
When they reach out to a shelter, women are often urged to prepare a safety plan, which includes a bag of clothes, copies of important documents, cash, medication, and in the case of pets, ownership papers and veterinary records. There are three shelters in the Interior of BC that offer on-site pet services, one each in Kelowna, Salmon Arm and Penticton, and the BC SPCA does offer an emergency shelter program for pets in cases of domestic violence.
Stevenson and her research partners have presented their work to the BC Society for Transition Houses with the goal of using this research to inform policy and reduce barriers to access. There is also significant advocacy for BC Housing to develop more pet-friendly housing.
Dr. Rochelle Stevenson
rstevenson@tru.ca
If you are in danger, please call 9-1-1, or call VictimLink BC at 1-800-563-0808 | Text: 604-863-6381
Read more posts by: Danna
Category: Arts, Featured, Homepage, Research
Tags: faculty research, funded research, published research
Research at TRU: A year worth celebrating
Bat research breaking new ground


Registration is May 2nd & 3rd (times to the left).
Tours will be offered from 8:00-12:00 on May 2nd & 3rd. Please call the office to schedule a tour.
Beginning September 4th parents/guardians/family visitors will require lunch tickets to join their child for lunch.
**guardians/visitors must be on the parent approved "pick-up list" to eat lunch with a child.
** Walking with children to class after lunch is not allowed (visitors with red ID badge/sticker).
PRIDE: 6:00-6:45 in the back loop. If a PRIDE car enters the loop after 6:45 you will more than likely get blocked in.
Car riders dropping off: The back loop will be closed at 7:28. After that time you will need to park in the front parking lot and walk your children to the office.
Transportation changes: Please contact the office prior to 2:00. Additionally, children should not be checked out between 2:00-2:30.
Car Rider Pick-Up: Please have your child's OCE issued car tag on the dash or hanging from the rearview mirror.
PRIDE pick-up: Please wait until after 2:55 to enter the loop and sign out your child. If you are earlier than 2:50 you will need to park in the lot and walk to the the PRIDE office at the rear of the school.
Thank you Kroger (Veteran's Pkwy) for your continued support of Overall Creek. We appreciate all you do for our community.
New student music reviews coming this fall!


Fibromyalgia syndrome (FMS), a common chronic pain condition, is often incompletely treated by conventional medical therapies. It can cause disability, psychological distress, work-related absenteeism, increased use of healthcare resources, and result in the inability to carry out the tasks of daily living. The purpose of this quantitative, correlational study was to investigate the potential influence of laughter on affect and pain in individuals with FMS. Laughter produces beneficial effects on acute pain and on chronic pain in general and has been found to improve temporary affective states, but there have been no studies testing the effects of laughter on the pain and affect of fibromyalgia patients. Informing this study were the gate control and neuromatrix theories of pain, as well as the dynamic model of affect theory. The research questions addressed whether laughter frequency is associated with affect and or with perceived chronic pain levels in these individuals. Forty-one adult fibromyalgia patients documented all laughter episodes daily and assessed their pain and affective states 3 times per day for 14 days. Hierarchical regressions revealed that increased overall laughter frequency was significantly associated with decreases in overall pain and increases in overall positive affect but was not associated with measures of negative affect. Also, morning laughter frequency was predictive of increased afternoon and evening positive affect ratings, as well as with decreased afternoon pain ratings, but was not significantly associated with evening pain ratings. The knowledge gained from these results may have positive social change implications at the individual level, within those individuals' larger social networks, and within the research and medical communities.


text:
Ray Brescia
Professor Brescia combines his experience as a public interest attorney in New York City with his scholarly interests to address economic and social inequality, the legal and policy implications of financial crises, how innovative legal and regulatory approaches can improve economic and community development efforts, and the need to expand access to justice for people of low and moderate income. He is the author of "The Future of Change: How Technology Shapes Social Revolutions" (Cornell University Press, 2020), which examines the intersection of technology and social movements, from the American Revolution, to the present day. He is also the co-editor of two books: Crisis Lawyering: Effective Legal Advocacy in Emergency Situations" (New York University Press, 2021); and "How Cities Will Save the World: Urban Innovation in the Face of Population Flows, Climate Change, and Economic Inequality (Routledge 2016).
Are you good in a crisis? There may be a growing practice area for you
Ray Brescia and Eric K. Stern discuss their book, Crisis Lawyering: Effective Legal Advocacy in Emergency Situations, their experiences, and delve into the ethical issues the legal profession should be examining as its members are forced to make hard choices in crisis situations.


text:
Q: Best practices for feature selection? I have datasets that range from ~2000-9000 columns of predictor variables.  I'm often charged with primarily classification - but sometimes regression tasks.   I know that I don't need this many variables for my models to be effective but I can't anticipate which ones in a reliable way.
I'm looking for ideas on the general best practices that would cut this down to around 50-150 variables which from my experience, seems fairly effective in determining the outcome.
Currently I'm using lasso or random forest to whittle down the number of variables before running a final model.  I want less variables so theres less noise, simply don't need that many, and to make it easier to deploy to production.

A: I think you are doing a "best practice" approach already for feature selection.
Using a regularised regression approach like LASSO and complementing those insights with a distribution-free model like Random Forest to decide the most important features is probably the best way to go.
Some minor suggestions: I would propose using Elastic Net to potentially have a small amount of $L_2$ regularisation. This should make our feature selection a bit more stable in case of correlated features. Similarly, taking a slightly more sophisticated approach of using Random Forests within a full Recursive Feature Elimination framework like Baruta (See Nilsson et al. for background, CRAN link) instead of simply relying on simple Random Forest variable importance will probably be beneficial.
Having said the above, we should use such feature selection approaches only if we cannot work with our original full dataset and/or we have problem collecting the features in question in the future (eg. too costly). Using a modelling approach that can actively regularise the resulting model (eg. gradient boosting machines where we can regularise the fit by properly picking the learning rate, tree-depth, minimum number of children per leaf node, etc.) is the best way to go. In that way we know we are not reusing our data, as well as that we are not losing valuable information that was potentially missed out during our feature selection step.
An issue, not touched upon is performing data reduction using some dimensionality reduction technique like PCA, ICA, NNMF, etc. These techniques do not "select features" per se but rather "combine features" to create meta-features of variable informational value. They can be very useful if we need a small subset of "information-rich" features. Nevertheless, these "information-rich" features are not guarantee to include more, less or any information relevant to our modelling task so they are not a silver bullet for feature selection. They usually present a convenient and condensed representation of our original data when we cannot work with their raw form.

redpajama_set_name: RedPajamaStackExchange


FAQ: How can I create a backup of my data?
You can use the export functions of the different modules to make a backup of the desired data.
2. Next click on My backups and on the plus sign to start generating a backup.
3. No need to wait here if you have a lot of data, Teamleader will notify you when the file to download is ready.
Teamleader keeps a maximum of 3 files for 24 hours. So, if you created four backups at 8am, 11am, 1pm and 5pm, you would only see the last three ones. Each of them will be shown for 24h, so the one from 11am today will be visible until 11am tomorrow. You can of course also store the file locally.
This option is not available in a trial account.
Only an admin user can create backups.
The backup will provide the data from the entire account, not only the data from the user that exports it.
The notes/tracking on any level in Teamleader.
Article lines on quotations/invoices. You can however export these via Deals > Export or Invoices > Export.
The pdf's generated in Teamleader. You can however export invoices in PDF via Invoices > Export > Batch export invoices to PDF.
Other files you've uploaded to the 'Files' of a certain customer/project. Looking for a fast way to sync them to your computer? Read more on our Dropbox integration here.
Tickets: the content of your tickets cannot be exported, only the ticket properties.


This sprightly arrangement of a classic gospel hymn will encourage and uplift! Written in the keys of Bb and C for late intermediate/early advanced pianists. This arrangement works well as a postlude, offertory, or even recital piece.


text:
Black-and-yellow Silky-flycatcher Long-tailed Silky-flycatcher
Gray Silky-flycatcher Ptiliogonys cinereus
Family: Ptiliogonatidae
© Juan Miguel Artigas Azas
The Gray Silky-flycatcher is almost endemic to Mexico, although it just ranges into western Guatemala. Like the entire family, this is an attractive and easily identified species: the upperparts are brownish gray to pure gray, with a long, slender tail and a prominent crest, a noticeable pale eye-ring, bright yellow ventral feathering, and the rest of the underparts vary (with subspecies and sex) from deep gray to golden olive. These birds feed on both insects and fruits, and are typically found in montane forests, although they range into more open areas provided there are scattered trees. Their habit of making airborne sallies for prey and perching prominently makes them easy to observe.
Andrew Spencer
Macaulay Library ML28126781 eBirdS29396200
© Andrew Spencer
Gray Silky-flycatcher (Ptiliogonys cinereus), In Neotropical Birds Online (T. S. Schulenberg, Editor). Cornell Lab of Ornithology, Ithaca, NY, USA. retrieved from Neotropical Birds Online: https://neotropical.birds.cornell.edu/Species-Account/nb/species/grsfly1


It is the biological system of immune response of an individual against its own cells and tissues. The disease caused due to aberrant immune response is called autoimmune disease.
Immunome Research, Journal of Clinical & Cellular Immunology, Journal of Immunooncology, Journal of Autoimmune Diseases, Autoimmune Diseases, Handbook of Systemic Autoimmune Diseases, Journal of Autoimmunity, Autoimmunity Reviews.


text:
The 1922 North Carolina State Wolfpack football team was an American football team that represented the NC State Wolfpack of North Carolina State University during the 1922 college football season. In its third season under head coach Harry Hartsell, the team compiled a 4–6 record.

Schedule

References

NC State
NC State Wolfpack football seasons
NC State Wolfpack football

redpajama_set_name: RedPajamaWikipedia


Are you interested in studying the processes of how life on Earth began, evolved and diversified? Do you enjoy getting your hands dirty as well as spending time in the lab?
Get ready to dig up the past on our BSc (Hons) Palaeontology degree course. You'll learn the theory and methodology of palaeontology and get a solid foundation in geology. By using our comprehensively equipped labs and journeying to the past on field trips, you'll graduate with skills to apply your knowledge in a range of scientific roles in areas from oil exploration to museum curation.
This degree course is accredited by The Geological Society, which means teaching is of the highest quality, and has been approved by an independent body of academics and industrialists. This gives you an edge over students who didn't do an accredited course when you're applying for jobs.
This accreditation also allows you to become a Chartered Geologist or Chartered Scientist more quickly once you've completed the course.
When you finish the course, our Careers and Employability service can help you find a job that puts your skills to work in the industry. If you want to continue your studies we can also help you identify relevant courses or research opportunities.
After you leave the University, you'll get help, advice and support for up to 5 years from our Careers and Employability service as you advance in your career.
The lecturers are helpful and enthusiastic, and there is a lot of new lab equipment as well as extensive fossil collections. There are also fantastic opportunities for fieldtrips.
After your second year, you can do an optional work placement year to get valuable longer-term work experience in the broad earth sciences sector.
Previous students from the School have enjoyed placements at organisations such as civil engineering, mining and quarrying companies and the Dinosaur Isle museum on the Isle of Wight.
We can help you look for a work placement that fits your aspirations. If you do a placement you'll get mentoring and support throughout the year.


officiallondontheatre.co.uk receives about 4,018 unique visitors and 12,054 (3.00 per visitor) page views per day which should earn about $54.12/day from advertising revenue. Estimated site value is $23,305.53. According to Alexa Traffic Rank officiallondontheatre.co.uk is ranked number 143,953 in the world and 0% of global Internet users visit it. Site is hosted in London, H9, United Kingdom and links to network IP address 213.52.233.117. This server doesn't support HTTPS and doesn't support HTTP/2.
How socially engaged is officiallondontheatre.co.uk?
How much officiallondontheatre.co.uk can earn?
How much money do officiallondontheatre.co.uk lose due to Adblock?
How much is officiallondontheatre.co.uk worth?
How fast does officiallondontheatre.co.uk load?
officiallondontheatre.co.uk does not use compression.
What sites are related to officiallondontheatre.co.uk?